HYPERFERRITINEMIA PREDICTS LONG-TERM MORTALITY IN PATIENTS WITH NAFLD.

Armandi A¹, Younes R², Caviglia GP¹, Petta S³, Miele L^{4,5}, Rosso C¹, Pennisi G³, Francione P⁶, Liguori A⁵, Govaere O⁷, Fracanzani AL⁶, Eslam M⁸, Valenti L⁶, George J⁸, Romero Gómez M⁹, Anstee QM⁷. Bugianesi E¹.



n=15

n=27

n=29

n=24

p < 0.001

F4

F3

F2

F1

F0

1 Department of Medical Sciences, Division of Gastroenterology and Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy; 2 Boehringer Ingelheim International, GmbH, Ingelheim, Germany; 3 Sezione di Gastroenterologia, Dipartimento Biomedico di Medicina Interna e Specialistica, Universita` di Palermo, Palermo, Italy; 4 Area Medicina Interna, Gastroenterologia e Oncologia Medica, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy; 5 Universita` Cattolica del Sacro Cuore, Rome, Italy; 6 Unit of Medicine and Metabolic Disease, Department of Pathophysiology and Transplantation, Ca' Granda IRCCS Foundation, Policlinico Hospital, University, Newcastle Liver Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom; 8 Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, Australia; 9 Unit for Clinical Management (UCM) Digestive Diseases and Ciberehd, Virgen del Rocío University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain

INTRODUCTION:

Hyperferritinemia is common in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and correlates with the severity of liver fibrosis. Our aim was to assess the impact of ferritin on long-term outcomes and survival in a large cohort of NAFLD patients.

METHODS:

We included 1247 patients with biopsy-proved NAFLD from tertiary centers in Italy (Turin, Milan, Rome, Palermo), Australia (Sydney), UK (Newcastle) and Spain (Seville). Clinical and biochemical data were collected at the time of liver biopsy (Table 1). Ferritin levels of 300 ug/L for men and 200 ug/L for women were considered as the upper limit of normal (ULN). Clinical outcomes, including liver-related events (ascites, encephalopathy, variceal bleeding), hepatocellular carcinoma (HCC) and survival, were collected after a median follow-up of 90 months.

RESULTS:

The median age of the study cohort was 48 [IQR 38-57] years and 814 (65.3%) patients were male. The overall prevalence of obesity and type 2 diabetes was 45.0% and 28.1%. Overall, hyperferritinemia was found in 373 (29.9%) patients; severe fibrosis (F3-4) was found at liver biopsy in 272 (21.8%) patients. NASH was diagnosed in 756 (60.6%) cases and was similarly distributed between those with normal and high ferritin levels. Serum ferritin $> 2 \times ULN$ (32.2% of the total population with hyperferritinemia), significantly associated with F3-4 (OR = 2.10 [95% CI 1.40-3.14], p < 0.001) (Figure 1).

After a median follow-up of 90 months, 24 patients (2.3%) died, while 57 (4.8%) and 18 (1.5%) developed liver-related events and HCC. At univariate analysis, the incidence of liver-related events and mortality varied significantly according to serum ferritin values > $2 \times ULN$ (log-rank test: p = 0.004 and p = 0.001, respectively) (Figures 2 and 3).


However, at multivariate Cox regression analysis adjusted for age, body mass index, diabetes and fibrosis, ferritin levels > 2 x ULN independently predicted mortality (HR = 3.04 [95% CI 1.16-7.93], p = 0.023) but not liver-related events (HR = 1.67 [95% CI 0.90-3.11], p = 0.105).

CONCLUSIONS:

Ferritin levels higher than 2 x ULN are associated with severe liver fibrosis in NAFLD patients and are able to predict long-term mortality.

Total population (n=1247)	Low ferritin (n=874)	High ferritin (n=373)	р
Age (years), median [IQR]	46 [37-56]	51 [40-59]	<0,001
Gender (M), n (%)	544 (62,2)	270 (72,4)	<0,001
BMI (Kg/m²), median [IQR]	29,6 [26,2-34,9]	29,4 [26,5-32,8]	0,231
Waist circumference (cm), median [IQR]	100 [92-110]	102 [95-108]	0,351
ALT (U/L), median [IQR]	56 [39-80]	69 [43-101]	<0,001
AST (U/L), median [IQR]	35 [27-48]	41 [29-64]	<0,001
GGT (U/L), median [IQR]	65 [37-122]	61 [33-118]	0,322
ALP (U/L), median [IQR]	83 [65-110]	71 [59-93]	<0,001
Albumin (g/L), median [IQR]	45 [43-48]	46 [43-49]	0,078
Total bilirubin (mmol/L), median [IQR]	10,3 [7,9-14,9]	12,0 [8,0-15,4]	<0,001
Platelets (10º/L), median [IQR]	234 [196-280]	215 [180-253]	<0,001
Hemoglobin (g/dL), median [IQR]	14,6 [13,3-18,0]	15,0 [14,0-16,0]	<0,001
Creatinin (mg/dL), median [IQR]	0,8 [0,7-1,0]	0,8 [0,7-1,0]	0,989
Blood glucose (mmol/L), median [IQR]	5,3 [4,8-6,2]	5,3 [4,8-6,3]	0,630
HDL (mmol/L), median [IQR]	1,3 [1,1-1,5]	1,2 [1,0-1,4]	<0,001
Triglycerides (mmol/L), median [IQR]	1,5 [1,1-2,1]	1,7 [1,1-2,2]	<0,001
Diabetes , n (%)	238 (27,2)	113 (30,3)	0,272

Table 1. Population characteristics



hyperferritinemia and fibrosis stages.






Figure 2. Cumulative incidence of liver-related events.





Funded by:

Horizon2020 under grant agreement: no.634413, EPoS; no.777377, LITMUS.

The Italian Ministry for Education, University and Research (Ministero dell'Istruzione, dell'Università e della Ricerca - MIUR) under the programme "Dipartimenti di Eccellenza 2018 – 2022" Project code D15D18000410001.

100

90

70

60

40

20

~ 50 n=15

n=46

n=69

n=55